| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
(R)-1,2,3,4-Tetrahydro-3-isoquinolinecarboxylic acid does not have a specific therapeutic target but is used as a building block in drug discovery. When incorporated into peptides or peptidomimetics, the rigid isoquinoline ring system can enhance target binding affinity, selectivity, and metabolic stability. It is commonly used to replace phenylalanine residues in bioactive peptides to improve their pharmacological properties.
|
|---|---|
| ln Vitro |
In vitro, this compound is primarily used as a building block in peptide synthesis. Its activity is dependent on the final peptide or peptidomimetic into which it is incorporated. The conformationally constrained structure can improve the bioactivity of peptides by reducing conformational flexibility and enhancing target interactions. Its effects are characterized through the biological assays of the resulting peptides.
|
| ln Vivo |
In vivo, (R)-1,2,3,4-Tetrahydro-3-isoquinolinecarboxylic acid is not typically administered as a standalone compound. Its pharmacological effects are observed through the peptides or drugs that incorporate this building block. These compounds may exhibit enhanced stability, bioavailability, and target engagement compared to their parent peptides.
|
| Enzyme Assay |
For in vitro peptide synthesis, (R)-1,2,3,4-Tetrahydro-3-isoquinolinecarboxylic acid is used as a protected or unprotected amino acid building block. Standard solid-phase peptide synthesis (SPPS) protocols are employed, using Fmoc or Boc protection strategies. The compound is coupled to the growing peptide chain using standard coupling reagents such as HBTU, HATU, or DIC. After synthesis, the peptide is cleaved from the resin and deprotected, then purified by HPLC.
|
| Cell Assay |
For in vitro cell-based assays, the peptides containing (R)-1,2,3,4-Tetrahydro-3-isoquinolinecarboxylic acid are tested on relevant cell lines depending on the target of the peptide. Cells are treated with the peptide at various concentrations (typically 1 nM-10 µM) for 24-72 hours. Cell viability, receptor binding, or signaling pathway activation is assessed using standard biochemical and cell-based assays.
|
| Animal Protocol |
For in vivo animal experiments, the peptides containing (R)-1,2,3,4-Tetrahydro-3-isoquinolinecarboxylic acid are typically administered intravenously, subcutaneously, or intraperitoneally to rodents. The compound's pharmacokinetic and pharmacodynamic properties are evaluated through the peptide's activity. Endpoints depend on the therapeutic target of the peptide and may include tumor volume, blood pressure, or inflammatory markers.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for (R)-1,2,3,4-Tetrahydro-3-isoquinolinecarboxylic acid itself are limited, as it is used as a building block rather than a therapeutic agent. When incorporated into peptides, it can enhance metabolic stability by reducing proteolytic degradation. The compound has a molecular weight of 177.20 g/mol and formula C₁₀H₁₁NO₂. Its properties contribute to the overall ADME profile of the final peptide.
|
| Toxicity/Toxicokinetics |
Toxicological data for (R)-1,2,3,4-Tetrahydro-3-isoquinolinecarboxylic acid are limited. As an amino acid analog, it is generally considered to have low toxicity. However, the safety profile depends on the final peptide or drug containing this building block. The compound is classified as a research-grade reagent and is not for human therapeutic use. Standard laboratory safety practices should be followed when handling.
|
| References | |
| Additional Infomation |
D-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic acid is a member of the isoquinoline class of compounds.
(R)-1,2,3,4-Tetrahydro-3-isoquinolinecarboxylic acid is a research-use only compound and has not been approved for clinical applications. It is also known as (R)-Tic, D-Tic, and D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid. Its molecular weight is 177.20, and its formula is C₁₀H₁₁NO₂. The compound is available from various research chemical suppliers for peptide synthesis and drug discovery applications. |
| Molecular Formula |
C10H11NO2
|
|---|---|
| Molecular Weight |
177.1998
|
| Exact Mass |
177.078
|
| CAS # |
103733-65-9
|
| PubChem CID |
712398
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
372.0±42.0 °C at 760 mmHg
|
| Flash Point |
178.8±27.9 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.577
|
| LogP |
0.86
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
13
|
| Complexity |
205
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1[C@@H](NCC2=CC=CC=C21)C(=O)O
|
| InChi Key |
BWKMGYQJPOAASG-SECBINFHSA-N
|
| InChi Code |
InChI=1S/C10H11NO2/c12-10(13)9-5-7-3-1-2-4-8(7)6-11-9/h1-4,9,11H,5-6H2,(H,12,13)/t9-/m1/s1
|
| Chemical Name |
(3R)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~1 mg/mL (~5.64 mM)
DMSO :< 1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.6433 mL | 28.2167 mL | 56.4334 mL | |
| 5 mM | 1.1287 mL | 5.6433 mL | 11.2867 mL | |
| 10 mM | 0.5643 mL | 2.8217 mL | 5.6433 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
